Innate Pharma S.A. ADS (IPHA)
Stock · NASDAQ · Health Care
$1.43as of 10/16/2026
Price chart
Active signals
IPHA Signal Track Record
How signals performed across all stocks →What IPHA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -4.3% | 37% | October 5, 2026 |
| Bollinger Band Breakdown | 24 | +1.9% | 58% | September 10, 2026 |
| Bollinger Band Breakout | 24 | -6.2% | 21% | August 10, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +0.6% | 56% | September 23, 2026 |
| Any 20-session window (baseline) | -1.8% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 120
- Website
- www.innate-pharma.com/
Fundamentals
- 1-day range
- $1.49$1.68
- Market cap
- $167.42M
- P/E (trailing)
- —
- P/E (forward)
- -3.44
- EPS (trailing)
- $-0.51
- Dividend yield
- —
- Beta
- 1.01
- Avg. volume
- 157.5K
Forecasts
3 analyst ratings
Innate Pharma S.A. ADS Competitors
Chosen by industry and closest market cap.
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- ARMPArmata Pharmaceuticals Inc. Common Stock$3.37▲ 9.06%Market cap $172.54MP/E —$2.75$16.34
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| ARMP Armata Pharmaceuticals Inc. Common Stock | $172.54M | — | $3.37 | ▲ 9.06% | $2.75$16.34 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a TurnaroundYahoo · 10/8/2026
- Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Yahoo · 10/5/2026
- Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should KnowYahoo · 9/23/2026
- Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?Yahoo · 9/23/2026
- Innate Pharma S.A. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha · 9/22/2026
- Innate Pharma (IPHA) Q2 2026 Earnings Call TranscriptYahoo · 9/18/2026
- Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call TranscriptSeekingAlpha · 9/17/2026
- Innate Pharma Q2 Earnings Call HighlightsYahoo · 9/17/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 184.0K
- Total value held
- $235.5K
- Institutional holders
- 9
- Unknown81.2K
- Unknown43.5K
- Unknown43.4K
- Unknown10.1K
- Unknown4.7K
- Unknown861
- Unknown240
- Unknown10
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Innate Pharma Closes Sobi Deal, Receives Upgrade
Innate Pharma has finalized a deal with Sobi, providing new funding intended to keep drug trials on track. This development coincided with an upgrade to Buy status, signaling renewed analyst interest in the company. The stock currently trades near its 52-week low, making these corporate updates a key focus for investors monitoring the firm's progress.
Innate Pharma Closes Sobi Deal, Receives Upgrade. Innate Pharma has finalized a deal with Sobi, providing new funding intended to keep drug trials on track. This development coincided with an upgrade to Buy status, signaling renewed analyst interest in the company. The stock currently trades near its 52-week low, making these corporate updates a key focus for investors monitoring the firm's progress.